Teva : Launch of Authorized Generic of Provigil

Mar. 30, 2012-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces the launch of the authorized generic of Provigil® (modafinil). Provigil® is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.

This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has commenced... Teva Pharmaceutical's Press Release -

Cephalon : Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

March 29, 2010 - Cephalon, Inc. (Nasdaq: CEPH) announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL(R) (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

As the first company to study a treatment option to improve wakefulness associated with jet lag disorder, Cephalon worked closely with the FDA to design a special protocol assessment (SPA) that would evaluate the experience of a typical eastbound airline traveler... Cephalon's Press Release -

Cephalon, PROVIGIL Label Updates

Sept. 17, 2007 - Cephalon, Inc. (Nasdaq: CEPH) announced that it has finalized and shared with healthcare professionals revisions to the label for PROVIGIL(R) (modafinil) Tablets [C-IV], its wake-promoting agent... PROVIGIL and NUVIGIL each are indicated to improve wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), shift work sleep disorder and narcolepsy... Cephalon's Press Release -